Antonio Fernando Leis Filho

Mr. Antonio Fernando Leis Filho


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Patricia LainettiPatricia Lainetti
Patricia Lainetti
AFAntonio Fernando Leis Filho
Antonio Fernando Leis Filho
RLRenee Laufer-Amorim
Renee Laufer-Amorim
ABAlexandre Battazza
Alexandre Battazza
Carlos Eduardo Fonseca-AlvesCarlos Eduardo Fonseca-Alves
Carlos Eduardo Fonseca-Alves
Breast cancer (BC) is one of the most important cancers worldwide, and usually, chemotherapy can be used in an integrative approach. Usually, chemotherapy treatment is performed in association with surgery, radiation or hormone therapy, providing an increased outcome to patients. However, tumors can develop resistance to different drugs, progressing for a more aggressive phenotype. In this scenario, the use of nanocarriers could help to defeat tumor cell resistance, providing a new therapeutic perspective for patients. Thus, this systematic review aims to bring the molecular mechanisms involved in BC chemoresistance and extract from the previous literature information regarding the use of nanoparticles as potential treatment for chemoresistant breast cancer.

17 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AFAntonio Fernando Leis Filho
Antonio Fernando Leis Filho
Patricia LainettiPatricia Lainetti
Patricia Lainetti
PKPriscila Kobayashi
Priscila Kobayashi
Carlos Eduardo Fonseca-AlvesCarlos Eduardo Fonseca-Alves
Carlos Eduardo Fonseca-Alves
RLRenee Laufer-Amorim
Renee Laufer-Amorim
HER2 is a prognostic and predictive marker widely used in breast cancer. Lapatinib is a tyrosine kinase inhibitor that works by blocking the phosphorylation of the receptor HER2. Its use is related to relatively good results in the treatment of women with HER2+ breast cancer. Thus, this study aimed to verify the effects of lapatinib on four canine primary mammary gland carcinoma cell cultures and two paired metastatic cell cultures. Cultures were treated with lapatinib at concentrations of 100, 500, 1000 and 3000 nM for 24 h and the 50% inhibitory concentration (IC50) for each cell culture was determined. In addition, a transwell assay was performed to assess the ability of lapatinib to inhibit cell migration. Furthermore, we verified HER2 expression by RT-qPCR analysis of cell cultures and formalin-fixed paraffin-embedded tissues from samples corresponding to those used in cell culture. Lapatinib was able to inhibit cell proliferation in all cell cultures, but it was not able to inhibit migration in all cell cultures. The higher the expression of HER2 in a culture, the more sensitive the culture was to treatment. This relationship may be an indication that the expression of HER2 may be a predictive factor and opens a new perspective for the treatment of primary and metastatic mammary gland cancer.

Verified
Journal Article
Open access
PDF file
AFAntonio Fernando Leis Filho
Antonio Fernando Leis Filho
Patricia LainettiPatricia Lainetti
Patricia Lainetti
MFMayara Simão Franzoni
Mayara Simão Franzoni
Chiara PalmieriChiara Palmieri
Chiara Palmieri
PKPriscila Kobayashi
Priscila Kobayashi
Carlos Eduardo Fonseca-AlvesCarlos Eduardo Fonseca-Alves
Carlos Eduardo Fonseca-Alves
CD24 is a cell surface molecule anchored by glycosyl-phosphatidyl-inositol and expressed by different human cancers, including prostate cancer (PC). Some studies have demonstrated that CD24 expression is associated with poor patient outcome; however, few studies have investigated CD24 expression in spontaneous animal models of human PC, such as canine PC. This study aimed to evaluate the expression of CD24 in human PC using the in silico analysis of the data obtained from The Cancer Genome Atlas (TCGA) and comparing it with the previously published prostatic canine transcriptome data. In addition, CD24 expression was confirmed by immunohistochemistry in an independent cohort of canine prostatic samples and its prognostic significance assessed. The systematic review identified 10 publications fitting with the inclusion criteria of this study. Of the 10 manuscripts, 5 demonstrated a direct correlation between CD24 overexpression and patient prognoses. CD24 expression was also associated with PSA relapse (2/5) and tumor progression (1/5). However, the in silico analysis did not validate CD24 as a prognostic factor of human PC. Regarding canine PC, 10 out of 30 normal prostates and 27 out of 40 PC samples were positive for CD24. As in humans, there was no association with overall survival. Overall, our results demonstrated a significant CD24 overexpression in human and canine prostate cancer, although its prognostic value may be questionable. However, tumors overexpressing CD24 may be a reliable model for new target therapies and dogs could be used of a unique preclinical model for these studies.

9 December 2024 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
FTFwu Shing Teng
Fwu Shing Teng
Patricia LainettiPatricia Lainetti
Patricia Lainetti
MFMayara Simão Franzoni
Mayara Simão Franzoni
AFAntonio Fernando Leis Filho
Antonio Fernando Leis Filho
CMCRISTINA MASSOCO
CRISTINA MASSOCO
Carlos Eduardo Fonseca-AlvesCarlos Eduardo Fonseca-Alves
Carlos Eduardo Fonseca-Alves
Canine oral melanoma (COM) is a promising target for immunomodulatory therapies aimed at enhancing the immune system’s antitumor response. Given that adipose-derived mesenchymal stem cells (Ad-MSCs) possess immunomodulatory properties through cytokine release, we hypothesized that co-culturing Ad-MSCs and canine peripheral blood mononuclear cells (PBMCs) could stimulate interleukin (IL) production against melanoma cell lines (MCCLs) and help identify therapeutic targets. This study evaluated IL-2, IL-8, and IL-12 expressions in co-culture with MCCL, Ad-MSCs, and PBMCs and assessed the relationship between gene expression, cell viability, and migration. Using four experimental groups in a Transwell insert system to separate cell types, we found that Ad-MSCs can reduce MCCL migration and viability, though the effect may vary depending on each cell line’s susceptibility. Furthermore, Ad-MSCs modified IL expression profiles in co-cultured cells. Our findings suggest that Ad-MSCs could have therapeutic potential for COM by inhibiting cell migration and reducing viability. However, deeper insights into Ad-MSC interactions with the tumor microenvironment and melanoma-specific factors will be essential to optimize therapeutic efficacy.

29 May 2025 in Animals
Verified
Journal Article
Open access
PDF file
TSThayna Oliveira da Silva
Thayna Oliveira da Silva
LCLuís Ramos de Moraes Calheiros
Luís Ramos de Moraes Calheiros
FBFelipe Barbosa
Felipe Barbosa
FMFernanda B Morrone
Fernanda B Morrone
LRLiliana Rockenbach
Liliana Rockenbach
RLRenee Laufer-Amorim
Renee Laufer-Amorim
Bladder urothelial carcinoma (UC) is an aggressive malignancy in both humans and dogs, with limited treatment options. Owing to their biological and environmental similarities with humans, dogs serve as a valuable model for UC research. Standard treatments, including surgery, chemotherapy, and anti-inflammatory agents, have shown limited efficacy. Curcumin, a bioactive compound derived from turmeric, has demonstrated anticancer properties, but its potential in canine UC remains poorly understood. In this study, we evaluated the effects of curcumin, D6 turmeric, and mitoxantrone hydrochloride on canine and human UC cell lines. Cell viability was assessed via the MTT assay, apoptosis via flow cytometry, and gene expression (β-catenin, β1-integrin, CDH1, MMP-2, MMP-9, and TIMP-2) via quantitative PCR. Migration capacity was analyzed using a Transwell assay. Curcumin and D6 turmeric reduced cell viability and migration, while mitoxantrone hydrochloride exhibited strong cytotoxicity, especially in canine cells. Curcumin also induced apoptosis and modulated genes involved in epithelial–mesenchymal transition and invasion. The interindividual differences in response suggest underlying genetic variability and highlight the need for personalized therapeutic approaches. These findings suggest that curcumin and D6 turmeric hold promise as complementary therapies for canine UC, justifying further in vivo investigations.

5 May 2025 in Journal of Comparative Pathology
Verified
Journal Article
Closed access
PKPriscila Kobayashi
Priscila Kobayashi
Patricia LainettiPatricia Lainetti
Patricia Lainetti
AFAntonio Fernando Leis Filho
Antonio Fernando Leis Filho
FDFlavia Karina Delella
Flavia Karina Delella
IVIgor S.T. Vicente
Igor S.T. Vicente
RLRenee Laufer-Amorim
Renee Laufer-Amorim